亚宝药业：拟将太原制药62%的股权转让给同享科技

Core Viewpoint - The company plans to transfer 62% of its stake in its subsidiary, Taiyuan Pharmaceutical Co., Ltd., to Shanxi Tongxiang Times Technology Co., Ltd. for a transaction price of RMB 87.1887 million [1] Group 1 - After the transaction, Tongxiang Technology will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements following the completion of the transaction [1]